Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 191-195

  Ogawara, Daiki ^a   Fukuda, Minoru ^b   Nakamura, Yoichi ^c   Kohno, Shigeru ^c  

^a Sasebo Central Hospital   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amrubicin; Amrubicinol; Relapse; Small cell lung cancer

Indexed keywords

AMRUBICIN; AMRUBICINOL; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; DRUG METABOLITE; HYDROXYL GROUP; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ANEMIA; ANOREXIA; ASTHENIA; CANCER PATIENT; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; FEBRILE NEUTROPENIA; HUMAN; HYPONATREMIA; JAPANESE; LEUKOPENIA; LUNG SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 77957108540     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: None     Document Type: Review

References (12)

1. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17: 658-667.
2. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJOG) study. Invest New Drugs. 2007;25:253-258.
3. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85-91.
4. Yamaoka T, Hanada M, Ichii S, et al. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res. 1998;89:1067-1073.
5. Hanada M, Mizuno S, Fukushima A, et al. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res. 1998;89: 1229-1238.
6. Morisada S, Yanagi Y, Noguchi T, et al. Antitumor activities of novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res. 1989;80: 69-76.
7. Morisada S, Yanagi Y, Kashiwazaki Y, et al. Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res. 1989;80:77-82.
8. Suzuki T, Minamide S, Iwasaki T, et al. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin. Invest New Drugs. 1997;15:219-225.
9. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5448-5453.
10. Kaira K, Sunaga Y, Tomizawa Y, et al. A Phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer. 2009:3451-3456.
11. Jotte RM, Conkling PR, Reynolds C, et al. A randomized Phase 2 trial of amrubicin (AMR) vs topotecan as second-line treatment in extensivedisease small cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. J Clin Oncol. 2008;26(15S):8040.
12. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26:5401-5406.